Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibits viral replication
|
| gptkbp:approves |
gptkb:2018
gptkb:FDA |
| gptkbp:brand |
gptkb:Xofluza
|
| gptkbp:class |
polymerase acidic endonuclease inhibitor
|
| gptkbp:clinical_trial |
Phase 3
positive outcomes reported acute uncomplicated influenza various international sites |
| gptkbp:contraindication |
hypersensitivity to baloxavir
|
| gptkbp:developer |
gptkb:Shionogi_&_Co.
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:duration |
one dose
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
oral tablet
|
| gptkbp:healthcare |
necessary for proper use
significant in influenza management |
| https://www.w3.org/2000/01/rdf-schema#label |
Rapivab
|
| gptkbp:indication |
influenza virus infection
|
| gptkbp:ingredients |
gptkb:baloxavir_marboxil
|
| gptkbp:interacts_with |
minimal interactions
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
monitor for side effects
|
| gptkbp:is_used_for |
treatment of influenza
|
| gptkbp:lifespan |
approximately 35 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Shionogi
|
| gptkbp:metabolism |
not extensively metabolized
|
| gptkbp:packaging |
blister packs
|
| gptkbp:pharmacokinetics |
rapid absorption
inhibits viral RNA synthesis |
| gptkbp:population |
provided with prescription
immunocompetent patients |
| gptkbp:price |
varies by region
|
| gptkbp:provides_information_on |
included in treatment guidelines
|
| gptkbp:receives_funding_from |
supported by pharmaceutical company
|
| gptkbp:regulatory_compliance |
based on clinical trial data
|
| gptkbp:release_region |
multiple countries
|
| gptkbp:requires |
prescription only
|
| gptkbp:research |
numerous studies conducted
|
| gptkbp:research_focus |
influenza treatment
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:sales |
increasing
|
| gptkbp:side_effect |
headache
nausea diarrhea reported in clinical trials |
| gptkbp:storage |
store at room temperature
|
| gptkbp:suitable_for |
patients with severe renal impairment
|
| gptkbp:supply_chain |
managed by manufacturer
|
| gptkbp:supports |
granted in 2018
|
| gptkbp:target_audience |
adults and children 12 years and older
|
| gptkbp:treatment |
reduces duration of symptoms
|
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:year_created |
gptkb:2013
|
| gptkbp:bfsParent |
gptkb:Peramivir
|
| gptkbp:bfsLayer |
5
|